MG
PTCT icon

Marex Group’s PTC Therapeutics PTCT Stock Holding History

Marex Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$636K Buy
+9,334
New +$661K ﹤0.01% 562
2025
Q4 		– Sell
-3,692
Closed -$227K – 1108
2025
Q3 		$227K Buy
+3,692
New +$192K ﹤0.01% 686

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marex Group's PTCT Position: Q1 2026 in Review

Marex Group opened a new position in PTC Therapeutics (PTCT) in Q1 2026: 9,334 shares worth $636K. The stake represents ﹤0.01% of the portfolio and ranks #562 among its holdings. This is a return to the name: Marex Group previously reported a position in PTCT as recently as Q3 2025.

Marex Group first reported a position in PTCT in Q3 2025 and has held it in 2 quarters since. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Marex Group held 9,334 shares of PTC Therapeutics worth $636K as of Q1 2026.
  • PTC Therapeutics was a new Marex Group position in Q1 2026.
  • PTC Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #562 holding.
  • Marex Group first reported a position in PTC Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.